Results 91 to 100 of about 26,501 (228)

Transarterial chemoembolization for treatment of hepatocellular carcinoma: A single center experience

, 2013
Background/aims: We aimed to determine the effect of transarterial chemoembolization treatment on survival in patients with hepatocellular carcinoma and to investigate the efficacy and tolerability of two different transarterial chemoembolization ...
ERDOĞAN, BEYZA DOĞANAY, BALKANCI, FERHUN, BAYRAKTAR, YUSUF, Beyza DOGANAY ERDOGAN, Altundag, Kadri, YALÇIN, SIDDIKA SONGÜL, Ilkay IDILMAN, ÇİL, BARBAROS ERHAN, KAV, TAYLAN, Yusuf BAYRAKTAR, Barbaros Erhan CIL, Taylan KAV, Bora PEYNIRCIOGLU, İDİLMAN, İLKAY SEDAKAT, Kadri ALTUNDAG, Ferhun BALKANCI, PEYNİRCİOĞLU, BORA, Suayip YALCIN   +17 more
core   +1 more source

Construction of a Non‐Invasive Predictive Model Based on PIVKA‐II Combined With MRI Imaging Features for Evaluating Microvascular Invasion in Hepatocellular Carcinoma

The Kaohsiung Journal of Medical Sciences, Volume 42, Issue 10, October 2026.
ABSTRACT This study developed a non‐invasive model using PIVKA‐II and MRI features to predict microvascular invasion in hepatocellular carcinoma, providing a reliable tool for early risk assessment and personalized treatment planning. The study included 98 patients with pathologically confirmed HCC (Child‐Pugh A, BCLC stage A), comprising 43 MVI ...
Di Gao, Rui‐Qi Jin, Hong‐Wei Wang
wiley   +1 more source

Perioperative Camrelizumab and Apatinib for High‐Risk Resectable Hepatocellular Carcinoma: A Phase II Study

MedComm, Volume 7, Issue 10, October 2026.
In this study, perioperative camrelizumab plus apatinib demonstrated promising efficacy and safety in resectable hepatocellular carcinoma (HCC) patients at high risk of recurrence, achieving a major pathological response of 46.2%. The median disease‐free survival and progression‐free survival were 24.1 months and 18.3 months, respectively.
Yunlong Cui, Xu Bao, Ge Yu, Feng Fang, Qiang Li, Han Mu, Chen Liu, Qiang Wu, Wei Zhang, Huikai Li, Ping Chen, Xiaomeng Liu, Hongyuan Zhou, Tianqiang Song   +13 more
wiley   +1 more source

A Single-Center Retrospective Comparison of Doxorubicin-Loaded HepaSphere Transarterial Chemoembolization with Conventional Transarterial Chemoembolization for Patients with Unresectable Hepatocellular Carcinoma

, 2015
Purpose: To compare doxorubicin-loaded HepaSphere transarterial chemoembolization versus conventional transarterial chemoembolization in terms of survival, time to recurrence, acute reversible hepatotoxicity, postembolization syndrome, and ...
KÜÇÜKAY, FAHRETTİN, Bostanci, Erdal B., Ozdemir, Mustafa, Badem, Serife, Akdogan, Meral, Ozbulbul, Nilgun I., KÜÇÜKAY, MURAT BÜLENT, Karan, Adnan, Okten, Riza S., Unlu, Ipek   +9 more
core   +1 more source

Comparison of Transarterial Y90 Radioembolization and Conventional Transarterial Chemoembolization in Hepatocarcinoma Patients: A Meta-analysis

, 2020
Comparison of Transarterial Y90 Radioembolization and Conventional Transarterial Chemoembolization in Hepatocarcinoma Patients: A Meta ...
S Qin (13391970), L Ding (7749218), Erna Jia (7140389), Jinru Xue (11601940), Na Ren (692562)   +4 more
core   +1 more source

Efficacy and Safety of Co‐Ablation Combined With Aintilimab for Metastatic Melanoma to the Liver (CryoCheck‐001): A Phase II Trial

MedComm, Volume 7, Issue 10, October 2026.
Liver metastasis is a key driver of immune tolerance in patients with melanoma receiving immune checkpoint inhibitor therapy. This single‐arm phase II trial prospectively investigated the efficacy and safety of co‐ablation combined with sintilimab for liver metastatic melanoma.
Lujun Shen, Letao Lin, Shuanggang Chen, Chen Li, Ruizhi Tang, Lin Xie, Yujia Wang, Yunpeng Li, Hongliang Zou, Dandan Li, Xiaoshi Zhang, Weijun Fan   +11 more
wiley   +1 more source

Transarterial Chemoembolization [PDF]

JAMA Oncology, 2015
Howard Jack, West, Jill O, Jin
openaire   +2 more sources

Effectiveness of Transarterial Chemoembolization-First Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis

, 2021
Sung Won Chung,1,* Min Kyung Park,1,* Young Youn Cho,1,2,* Youngsu Park,1 Cheol-Hyung Lee,1 Hyunwoo Oh,1 Heejoon Jang,1 Minseok Albert Kim,1 Sun Woong Kim,1 Joon Yeul Nam,1 Yun Bin Lee,1 Eun Ju Cho,1 Su Jong Yu,1 Hyo-Cheol Kim,3 Yoon Jun Kim,1 Jin Wook ...
Chung SW, Kim SW, Yu SJ, Park MK, Oh H, Jang H, Yoon JH, Kim MA, Park Y, Lee YB, Lee CH, Cho YY, Nam JY, Kim YJ, Kim HC, Cho EJ, Chung JW, Lee JH   +17 more
core  

A Rare Case of Empyema Developed after Transarterial Chemoembolization for Hepatocellular Carcinoma

대한영상의학회지, 2015
A 60-year-old male patient who previously underwent transarterial chemoembolization for recurrent hepatocellular carcinoma three months ago presented to the emergency department with pleural effusion and hemoptysis.
Young Keun Sur, Je Hwan Won, Hee-Jung Wang, Jinoo Kim   +3 more
doaj   +1 more source

Hepatic arterial infusion chemotherapy for hepatocellular carcinoma refractory to transarterial chemoembolization: exploring the influence of prior transarterial chemoembolization and additional transarterial chemoembolization on survival outcomes

Journal of Gastrointestinal Oncology
The selection of an efficacious treatment modality for patients with hepatocellular carcinoma (HCC) diagnosed as refractory to transarterial chemoembolization (TACE) presents numerous challenges. In addition to systemic therapies, hepatic arterial infusion chemotherapy (HAIC) may serve as an alternative option.
Hien, Phan Nhan, Chun, Ho Jong, Oh, Jung Suk, Kim, Su Ho, Choi, Byung Gil   +4 more
openaire   +2 more sources